United States· US:50090-8022_617be39d-c5c3-461c-9267-2d0b0a57aa60

MOUNJARO

A tirzepatide product containing tirzepatide, registered in United States by A-S Medication Solutions. The same ATC class is registered in 15 of our 19 countries.

ATC A10BX16

Checked against FDA National Drug Code directory (United States) on

Informational only — not a medical device.

SOURCE REGISTER · USFDA National Drug Code directory (Unite…normalisedMOUNJAROATCA10BX16REGISTER NO.US:50090-8022_617be39…PACKS LISTED1CHECKEDSeptember 27, 2026

Where it is registered

Tirzepatide is registered in 15 of 19 countries.

Countries holding a registration under ATC A10BX16 (tirzepatide), each read from that country’s own register.

  • This record: United States, from FDA National Drug Code directory (United States)
  • 10 of them publish a price we can compare per daily dose

Tirzepatide · ATC A10BX16

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of tirzepatide costs, country by country.

Normalised to the WHO defined daily dose (1.4 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Tirzepatide · price per daily dose (1.4 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$45.12
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FDA National Drug Code directory (United States)
Active substance
TIRZEPATIDE
Manufacturer
A-S Medication Solutions
Country
United States (US)
ATC code
A10BX16
ATC class
Tirzepatide
Defined daily dose
1.4 mg, P
Reimbursed
Not published by this register
Source register
FDA National Drug Code directory (United States)
Last checked
September 27, 2026

Packs & prices · 1

  • ndc11
    50090-8022-0

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Tirzepatide in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All tirzepatide products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Mounjaro, Mounjaro Kwikpen
  • Liechtenstein · Mounjaro, Mounjaro Kwikpen
  • Norway · Mounjaro, Mounjaro Kwikpen

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/dc5825bb-900d-4465-98f8-a71af4ee719c
GET /v1/drugs/dc5825bb-900d-4465-98f8-a71af4ee719c?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "route": "SUBCUTANEOUS",
  "source": "ndc",
  "strength": "12.5",
  "substance": "TIRZEPATIDE",
  "productndc": "50090-8022",
  "dosage_form": "INJECTION, SOLUTION",
  "dea_schedule": null,
  "strength_unit": "mg/.5mL",
  "application_number": "NDA215866",
  "marketing_category": "NDA"
}

See everything about tirzepatide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.